NASDAQ: ELEVElevation Oncology Inc Stock
$0.60+0.01 (+1.69%)
Updated Sep 19, 2024
ELEV Price
$0.60
Fair Value Price
$0.56
Market Cap
$35.46M
52 Week Low
$0.36
52 Week High
$5.83
P/E
-0.76x
P/B
0.44x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$39.70M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.42
Operating Cash Flow
-$43M
Beta
0.9
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ELEV Overview
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, is developing cancer treatments for genomically defined patient populations. The company's lead program is seribantumab, in a Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology was incorporated in 2019 and is based in New York, NY.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ELEV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ELEV ($0.60) is overvalued by 6.95% relative to our estimate of its Fair Value price of $0.56 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ELEV ($0.60) is not significantly undervalued (6.95%) relative to our estimate of its Fair Value price of $0.56 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ELEV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ELEV due diligence checks available for Premium users.
Be the first to know about important ELEV news, forecast changes, insider trades & much more!
ELEV News
Valuation
ELEV fair value
Fair Value of ELEV stock based on Discounted Cash Flow (DCF)
Price
$0.60
Fair Value
$0.56
Overvalued by
6.95%
ELEV ($0.60) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ELEV ($0.60) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ELEV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ELEV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.76x
Industry
-135.85x
Market
25.52x
ELEV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.44x
Industry
6.51x
ELEV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ELEV's financial health
Profit margin
Revenue
$0.0
Net Income
-$10.5M
Profit Margin
0%
ELEV's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$114.6M
Liabilities
$33.7M
Debt to equity
0.42
ELEV's short-term assets ($113.57M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ELEV's short-term assets ($113.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ELEV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.2M
Investing
-$37.7M
Financing
$14.7M
ELEV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ELEV vs Biotech Stocks
Elevation Oncology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.